EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

DARS2 promotes the occurrence of lung adenocarcinoma via the ERK/c‐Myc signaling pathway

Tao Fang, Jin Jiang, Wenhao Yu, Rongyang Li, Hui Tian iD

Thoracic Cancer · 2023-12 · 14 (36) · 3511-3521

DOI: 10.1111/1759-7714.15152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 11.11.2023. Verfasst von Tao Fang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Adenocarcinoma, Aspartate-tRNA Ligase. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

DARS2 expression is upregulated in lung adenocarcinoma (LUAD) which correlates with tumor patient stage and prognosis. The mechanism of DARS2 involvement in LUAD still needs to be further explored.

Methods

In this study, we found that DARS2 expression in LUAD tissue was significantly higher than that in normal tissue. At the same time, the Kaplan–Meier curve showed that the survival prognosis of LUAD patients with high expression of DARS2 was significantly worse than low expression of DARS2. The expression of DARS2 was detected in LUAD and adjacent normal tissues by IHC staining, histochemical scoring and a survival curve was generated. In addition, we demonstrated that the knockdown and overexpression of DARS2 significantly affected the proliferation, invasion, and migration of LUAD cells in vitro and in vivo. Finally, western blot and rescue assay were performed on LUAD cells to further explore and verify the signaling pathway.

Results

DARS2 expression was significantly upregulated in LUAD tissues and cell lines. What is more, the increased expression of DARS2 was closely related to proliferation, invasion and metastasis. The tumorigenic assay in nude mice further showed that the tumorigenic ability of nude mice was significantly improved with the increase in DARS2 expression. Finally, we determined that DARS2 plays its role in LUAD by targeting the ERK/c‐Myc signaling pathway.

Conclusion

Our data revealed the oncogenic role of DARS2 in LUAD, indicating that DARS2 may be a predictive biomarker and novel therapeutic target for LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungAdenocarcinomaAspartate-tRNA LigaseAnimalsMiceHumansMice, NudeProto-Oncogene Proteins c-mycSignal TransductionCell Line, TumorCell ProliferationCell MovementGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

DARS2ERK/c-Myc signaling pathwaylung adenocarcinoma

Substanzen

Proto-Oncogene Proteins c-mycDARS2 protein, humanAspartate-tRNA Ligase

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.

ORCID-Profile: Hui Tian

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Fang, T., Jiang, J., Yu, W., Li, R., & Tian, H. (2023). DARS2 promotes the occurrence of lung adenocarcinoma via the ERK/c‐Myc signaling pathway. Thoracic Cancer, 14(36), 3511-3521. https://doi.org/10.1111/1759-7714.15152

Vancouver

Fang T, Jiang J, Yu W, Li R, Tian H. DARS2 promotes the occurrence of lung adenocarcinoma via the ERK/c‐Myc signaling pathway. Thoracic Cancer. 2023;14(36):3511-3521. doi:10.1111/1759-7714.15152

BibTeX
@article{Fang2023,
  author = {Fang, Tao and Jiang, Jin and Yu, Wenhao and Li, Rongyang and Tian, Hui},
  title = {DARS2 promotes the occurrence of lung adenocarcinoma via the ERK/c‐Myc signaling pathway},
  journal = {Thoracic Cancer},
  year = {2023},
  volume = {14},
  number = {36},
  pages = {3511--3521},
  doi = {10.1111/1759-7714.15152}
}
Kostenlos starten →